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Despite the discovery of heterotrimeric abg G proteins B25 years ago, their selective
perturbation by cell-permeable inhibitors remains a fundamental challenge. Here we report
that the plant-derived depsipeptide FR900359 (FR) is ideally suited to this task. Using a
multifaceted approach we systematically characterize FR as a selective inhibitor of Gq/11/14
over all other mammalian Ga isoforms and elaborate its molecular mechanism of action. We
also use FR to investigate whether inhibition of Gq proteins is an effective post-receptor
strategy to target oncogenic signalling, using melanoma as a model system. FR suppresses
many of the hallmark features that are central to the malignancy of melanoma cells, thereby
providing new opportunities for therapeutic intervention. Just as pertussis toxin is used
extensively to probe and inhibit the signalling of Gi/o proteins, we anticipate that FR will at
least be its equivalent for investigating the biological relevance of Gq.
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M
any extracellular stimuli propagate cellular activity via
G protein-coupled receptors (GPCRs), the largest
family of cell surface signalling molecules comprising
B800 members in humans1,2. Four families of heterotrimeric
abg guanine nucleotide-binding proteins (G proteins) located at
the cytoplasmic face of the plasma membrane sufﬁce to receive,
interpret and route these signals to diverse sets of downstream
target proteins3–8. Thus, the mammalian GPCR-G protein
signalling axis evolved to converge at the interface of receptor
and G protein to then diverge at the interface of G proteins and
effectors.
The mainstays of current pharmacotherapies are receptor
agonists or antagonists, but conditions with complex pathologies
such as cancer or pain, that involve multiple receptors and their
associated signalling pathways, may be treated by manipulation of
signalling at the post-receptor level9,10. Thus, pharmacological
efﬁcacy may be gained by targeting convergence points in
signalling cascades downstream of activated receptors.
Heterotrimeric G proteins are the ﬁrst step in the GPCR
signalling axis immediately downstream of activated receptors
and are precisely the type of convergence points that would
enable bypassing receptor diversity for the sake of increased
pharmacological efﬁcacy.
Although G proteins are of prime importance for maintaining
homoeostasis in response to extracellular cues, no pharmaco-
logical agent that would enable a therapeutic grip on this
protein family has become available since their discovery. Thus,
heterotrimeric G proteins of all four subclasses (Gs, Gi/o, Gq/11
and G12/13) may be perceived as undruggable despite numerous
cavities evident from X-ray crystallography that could be targets
for pharmacological intervention8,11. YM254890 (YM), a cyclic
depsipeptide of bacterial origin, co-crystallized together with its
target protein Gq, provided the ﬁrst high-resolution structure of a
G protein-inhibitor complex12. Unfortunately, YM has been
withdrawn by Astellas Pharma Inc. and is no longer available to
researchers. Also, inaccessible is the bacterial strain
Chromobacterium sp. QS3666 because it has not been deposited
in a public culture collection.
An alternative to YM, readily accessible to the scientiﬁc
community, is therefore needed urgently and would be of great
value to understand the contribution of Gq signalling in
physiology and disease, but also as a potential therapeutic target.
Here we propose that FR900359 (FR, previous commercial name
UBO-QIC, Fig. 1a) is such an alternative. Although ﬁrst isolated
in 1988 from the leaves of the ornamental plant Ardisia crenata13,
its speciﬁcity for individual Ga isoforms is unknown and has
never been studied systematically. Consequently, it is difﬁcult to
interpret the biological effects obtained with this reagent. We
characterize FR and its G protein selectivity proﬁle with the entire
set of mammalian Ga isoforms, and identify its molecular
mechanism of action using a panel of cell-based assays, puriﬁed
proteins and molecular dynamics simulations. We demonstrate
the analytical value of FR for the study of Gq activity in complex
signalling networks, both in living cells and in an ex vivo model of
Gq-mediated vasoconstriction. Importantly, we also demonstrate
that FR does not affect signalling and basic cell functions when
Gaq and Ga11 have been deleted by CRISPR-Cas9 genome
editing. Finally, we use FR to investigate the role of Gq proteins in
cancer cells using melanoma as a model system. Our results reveal
that silencing of Gq proteins rather than their linked receptors
may be an innovative yet underappreciated molecular inter-
vention to target oncogenic signalling at the post-receptor level.
Results
FR is Gq selective in second messenger assays. We puriﬁed FR
(Fig. 1a) by activity-guided fractionation of A. crenata leaf
extracts. Although FR is structurally closely related to YM
(Supplementary Fig. 1), we cannot rule out that subtle structural
differences may result in divergent functional activities.
Accumulation of inositol monophosphate (IP1) is an established
measure of Gq-coupled signalling to phospholipase Cb (PLCb)
isoforms14. Therefore, FR was initially assessed for its capacity to
blunt IP1 production in HEK293 cells on stimulation of three
distinct Gq-linked receptors (muscarinic M3 endogenously
expressed and free fatty acid receptors FFA1 and FFA2, forcibly
expressed in this cell system). Consistent with Gq inhibition,
ligand-mediated IP1 accumulation was completely suppressed by
FR in a concentration-dependent manner (Fig. 1b–d). Inhibition
proﬁles were non-competitive, independent of the chosen
Gq-sensitive receptor and the extent of basal receptor activity
that was low in native HEK293 cells but highly apparent
when constitutively active FFA1 and FFA2 were overexpressed
(Fig. 1b–d and Supplementary Fig. 2). FR concentrations
sufﬁcient to fully block Gq-mediated IP1 accumulation, did not
perturb the cAMP-raising by Gs-sensitive prostanoid EP2/EP4
receptors (Fig. 1e) or cAMP lowering by Gi-sensitive
prostaglandin D2 receptor DP2/CRTH2 (hereafter CRTH2;
Fig. 1f). An essentially identical selectivity proﬁle was obtained
when Gq-, Gs- and Gi-linked receptors were examined in Chinese
hamster ovary (CHO) cells as recombinant host (Fig. 1g–i).
Because FR is of plant origin, we wondered whether plants use
this molecule to regulate their own G protein signalling. Plant
G proteins are self-activating15, therefore we took advantage of
this property and monitored spontaneous GDP release of a plant
Gpa1 in the absence and presence of FR. We found that
concentrations of FR tenfold in excess of those sufﬁcient to fully
blunt mammalian Gq signalling hardly impacted the kinetics of
Gpa1 nucleotide exchange (Supplementary Fig. 3). Consistent
with this observation, FR did not alter Gpa1 thermal stability as
assessed by fast quantitative cysteine reactivity (Supplementary
Fig. 4). Together, our results suggest that FR is highly selective for
inhibition of mammalian Gq signalling and that this effect is
cell-type independent.
Selectivity of FR across all mammalian Ga isoforms. While
second messenger assays are well-suited to determine selectivity
of G protein inhibitors for the major Ga subfamilies, they cannot
discriminate between individual Ga isoforms. To provide an
accurate and comprehensive characterization of FR selectivity we
chose an experimental approach based on bioluminescence
resonance energy transfer (BRET) that relies on co-transfection
of GPCRs with an extended panel of Ga subunit sensors. In
particular, we applied Gas, Gai1, Gai2, Gai3, GaoA, GaoB, Gaq,
Ga11, Ga12, Ga13 fused to either RLucII or RLuc8, a more
sensitive BRET2 energy donor16, along with Gg2-GFP10 as energy
acceptor and unlabelled Gb1. This sensor combination has proven
valuable to monitor activation-associated conformational changes
within G proteins that occur upon receptor stimulation17,18.
HEK293 cells transiently transfected to express individual BRET
probes along with GPCRs from different coupling classes
responded with agonist-dependent BRET decreases that were
concentration dependent and well-suited to quantify activation
of all Ga isoforms (Fig. 2a–j). When cells were pretreated
with FR, agonist BRET responses of Gaq- and Ga11-containing
heterotrimers were completely prevented (Fig. 2a,b) but those of
all other Ga isoforms were not (Fig. 2c–j). As Ga-RLuc probes
were not available for Gq family members Ga14 and Ga16, we
took advantage of their ‘promiscuity’ to link non-Gq-GPCRs to
stimulation of the Gq-effector PLCb (refs 19,20) and thereby
production of IP1. HEK293 cells are an ideal host to reconstitute
such functional interaction as they express Gaq and Ga11 but not
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Ga14 or Ga16 (ref. 21). Indeed, both Ga14 and Ga16 translated
activation of the Gi-sensitive ORL1 receptor into robust
accumulation of IP1 on treatment with the cognate agonist
nociceptin (Fig. 2k,l). Yet, only ORL1-G14 but not -G16
interaction was fully prevented by FR (Fig. 2k,l). Nociceptin
was ineffective in cells transfected with empty vector, ORL1 or the
respective Ga proteins alone (Supplementary Fig. 5) conﬁrming
the speciﬁcity of the ‘reconstitution’ experiment. We further
interrogated whether inhibition by FR may be more speciﬁc to
any of the sensitive isoforms and quantiﬁed its capacity to blunt
signalling of individual Gq family members (Supplementary
Fig. 6). We found that inhibition of Gaq, Ga11 and Ga14
signalling by FR similarly required low micromolar
concentrations. In contrast, even in the presence of excess FR
signalling via Ga16 was completely unaffected. These results
illustrate that FR is highly selective for inhibition of Gaq, Ga11
and Ga14, and interdicts signal transduction by acting directly on
the G protein but not the GPCR.
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Figure 1 | FR interdicts Gaq-dependent second messenger production in mammalian cell lines. (a) Chemical structure of the cyclic depsipeptide FR
isolated from the leaves of A. crenata. (b–d) Agonist-induced IP1 production in HEK293 cells subsequent to stimulation of (b) endogenous muscarinic M3
receptors with CCh, (c,d) recombinant free fatty acid FFA2 and FFA1 receptors with propionic acid (C3) or small molecule FFA1 agonist TUG488,
respectively, in absence and presence of various concentrations of FR. (e) Prostaglandin E1 (PGE1)-induced increase in intracellular cAMP in HEK293 cells
with and without 1mM FR. (f) 13,14-dihydro-15-keto-prostaglandin D2 (DK-PGD2)-induced decrease in intracellular cAMP in CRTH2-HEK293 cells in
presence or absence of 1mM FR. (g,h) Agonist-induced second messenger production in CHO cells with or without FR (1mM). (g) Elevation of intracellular
IP1 mediated by Gq-linked M1 receptors stimulated in response to CCh. (h) PGE1-induced increase of intracellular cAMP via stimulation of endogenous,
Gs-sensitive prostaglandin EP2/4 receptors. (i) Iper-6-phth-mediated decrease in intracellular cAMP via Gi-linked muscarinic M2 receptors in M2-CHO
cells. (b–i) Data are means±s.e.m. of n¼ 2–8 experiments conducted at least in triplicate.
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FR does not impair G protein-independent b-arrestin recruitment.
b-arrestin proteins, known for their capacity to desensitize and
downregulate GPCR signalling22 also act as multiprotein scaffolds
that orchestrate proximity and function of signalling molecules
downstream of activated GPCRs23,24. b-arrestin recruitment to
activated receptors may occur both subsequent to or independent
of heterotrimeric G protein engagement24,25. Free fatty acid
receptor FFA4 and prostaglandin D2 receptor CRTH2 are two
examples for Gq- and Gi-linked receptors, respectively, where
G protein activation and b-arrestin recruitment operate
independent from each other26,27. Consistent with this notion,
Gq-independent b-arrestin recruitment by FFA4 was entirely
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Figure 2 | FR inhibits Gaq, Ga11 and Ga14, but not Ga16 or any other mammalian Ga isoform. (a–j) BRETexperiments conceived with Ga subunits fused to
energy donor RLucII or RLuc8, respectively, and Gg subunits fused to energy acceptor GFP10 in HEK293 cells transiently transfected to coexpress the
indicated BRETprobes. FR completely inhibits the activation of (a) Gaq-, and (b) Ga11-containing heterotrimers induced upon stimulation with angiotensin II
via coexpressed AT1 receptors. In (c–j) BRET recordings were obtained by coexpressing adrenergic a2C-AR (c,d), angiotensin II AT1 receptor (e–g,i),
arginine vasopressin V2 receptor (h), and thromboxane TPa receptor (j). Cells were initially pretreated with FR (0.1mM) or solvent and then stimulated
with the indicated agonists. (k,l) IP1 accumulation in HEK293 cells reconstituted by transient coexpression of the nociceptin ORL1 receptor along with Ga14
or Ga16, respectively, in absence and presence of 1 mM FR. Data are means±s.e.m. of n¼ 3–6 independent experiments conducted at least in triplicate.
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insensitive to FR pretreatment (Fig. 3a), but activation of
extracellular signal-regulated kinases 1 and 2 (ERK1/2), a
cellular event known to be largely Gq-mediated28, was not
(Fig. 3b,c). In fact, FFA4-CHO cells pretreated with FR displayed
diminished ERK activation at all doses of FFA4 agonist TUG891
(Supplementary Fig. 7). Consistent with these ﬁndings,
Gq-dependent IP1 accumulation was also entirely blunted by
FR (Supplementary Fig. 8). Similarly, pertussis toxin (PTX) fully
prevented CRTH2-dependent lowering of cAMP (Fig. 3d), but
was without effect on Gi-independent b-arrestin recruitment
triggered with the cognate agonist for this receptor (Fig. 3e).
Again, FR did not interfere with this G protein-independent
cellular event (Fig. 3f), highlighting its capacity to discriminate
between Gq-dependent and b-arrestin-promoted cell behaviours.
FR unmasks Gq signalling in whole-cell activation proﬁles. An
intrinsic property of many activated GPCRs is their initiation of
multiple signalling waves via engagement of heterotrimeric G
proteins and/or b-arrestins, respectively, a phenomenon referred
to as coupling multiplicity or coupling pleiotropy24,29. In this
regard holistic label-free detection platforms based on dynamic
mass redistribution (DMR) or bioimpedance may be
advantageous, because they provide unbiased, real-time kinetic
resolution of complex GPCR signalling in living cells30,31. We
initially investigated the consequences of pharmacological Gq
inactivation on integrated cell responses of GPCRs from all
four coupling classes including one with dual pathway coverage.
DMR response proﬁles elicited by ATP and carbachol (CCh),
which stimulate endogenous Gq-linked P2Y and muscarinic M3
receptors, respectively, were virtually abolished by FR (Fig. 4a,b).
In contrast, activity traces triggered by TUG424 via the
Gq/Gi-linked FFA1 receptor were only abrogated when FR was
combined with the Gi inhibitor PTX (Fig. 4c). Stimuli acting via
bona ﬁde receptors for Gs-, Gi- and G12/13-mediated signalling
were unaffected by pretreatment with FR (Fig. 4d–f). Essentially
similar ﬁndings were obtained when these experimental settings
were recapitulated using bioimpedance-based cell sensing
(Fig. 4g–l). FR, on its own, did not elicit detectable cell
activation (Supplementary Fig. 9) and stimuli chosen for Gs, Gi
and G12/13 engagement were validated to reﬂect the signalling
pathways previously assigned to them (Supplementary Fig. 10,
also see ref. 30 for comprehensive validation of receptor
signatures with antagonists, pathway modulators and second
messenger assays). From these results we infer that FR is highly
selective for inhibition of Gq-dependent signalling outcomes and
well-suited to investigate contribution of Gq input to complex
cell-activation proﬁles.
FR is inactive in cells lacking Gaq/11. To further corroborate
speciﬁcity of FR action in phenotypic assays we examined its
capacity to affect signalling and function in HEK293 cells lacking
functional Gq proteins by CRISPR-Cas9-mediated genome
editing. We targeted the genes coding for Gaq and Ga11 because,
among the four members of the Gaq family, Gaq and Ga11, but
not Ga14 and Ga16, are expressed in HEK293 cells21. Consistent
with the absence of Gaq/11 as determined by western blot analysis
(Fig. 5a), bona ﬁde Gq-stimuli ATP and CCh were markedly
impaired (ATP) or completely inactive (CCh) in holistic DMR
recordings on Gaq/11 knockout cells (Fig. 5b). However,
reintroduction of Gaq into the knockout background was
required and sufﬁcient to fully restore both, agonist responses
and their inhibition by FR (Fig. 5c). Essentially equivalent results
were obtained when the above stimuli were applied in single-cell
Ca2þ recordings (Fig. 5d,e). On its own, FR did not alter global
cell function irrespective of the presence or absence of Gaq/11
(Supplementary Fig. 11). To further assess potential off-target
activity of FR we analysed cell viability in parental and Gaq/11
knockout cells exposed to FR. We ﬁnd that FR does not disturb
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cellular metabolic homoeostasis even at concentrations by far
exceeding those to silence Gaq/11 signalling (Fig. 5f). Absence of
Gq-independent effects were also evident from phenotypic assays
examining alterations of basic cellular functions in cells lacking
Gaq/11. FR did not alter cell growth (Fig. 5g), the percentage of
proliferating cells as determined by staining for the nuclear cell
cycle marker Ki67 (Fig. 5h), apoptosis rate as quantiﬁed by life
cell Annexin V staining (Fig. 5i) or distribution of vimentin
ﬁlaments in the cytoplasm as potential indicator of morphological
abnormalities (Fig. 5j). Together, knockout and rescue
experiments along with the lack of measurable phenotypes in
response to FR using cells with Gaq/11 deletion, unambiguously
prove that inhibition of cellular functions by FR is mediated via
direct targeting of Gq.
Action of FR in a model of Gq-mediated vasoconstriction.
We next sought to expand our studies on FR action from cells to
more complex and physiologically relevant organ systems.
Many potent vasoconstrictors such as norepinephrine, endothelin
or angiotensin elicit their effects via Gq-GPCRs, thereby con-
tributing to the regulation of vascular tone and blood pressure.
We focused on phenylephrine (PE), an a1 adrenergic receptor
(a1AR) agonist, previously thought to modulate vascular tone
via interaction with Gq/11 proteins and their downstream
signalling components32. Speciﬁcally, we investigated whether
pharmacological Gq inactivation is required and sufﬁcient to
counteract PE-dependent increase of vascular tone using ex vivo
preparations of mouse tail arteries, an established model for
physiologically relevant resistance arteries. When arteries were
submaximally pre-constricted with PE, FR but not its solvent
strongly reduced vascular tone (Fig. 6a,b). On the contrary,
FR was essentially inactive when tail arteries were submaximally
pre-constricted with the receptor- and Gq-independent
vasoconstrictor KCl (Fig. 6b,c), conﬁrming the Gq-speciﬁc
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nature of the observed relaxation. Interestingly, vascular
relaxation by FR was apparently irreversible because
PE-mediated constriction did not re-emerge even after
extensive washout of FR (Fig. 6a,c). This lack of PE-effect is
not due to deterioration of the preparations because vessels
remained responsive to the Gq-independent vasoconstrictor KCl
(Fig. 6a,c). Our ﬁndings validate PE-dependent, a1AR-mediated
vasoconstriction as an ex vivo Gq paradigm and nicely illustrate
the value of FR as a powerful pharmacological agent to unmask
Gq contribution even in more complex ex vivo settings.
FR inhibits activation of Gq in a pseudo-irreversible manner.
Resistance to washout of FR-dependent vasorelaxation may be
indicative of covalent or at least very tight interaction between FR
and its target Gq. Alternatively, FR may accumulate near its target
or be hindered in free diffusion away from its target in the
complex ex vivo setting. Indeed, FR carries an a,b-unsaturated
carbonyl group of an N-methyldehydroalanine (N-MeDha)
residue, which may be susceptible to nucleophilic attack, for
instance via Michael addition (Supplementary Fig. 12a). Thus,
it is conceivable that FR inhibition of Gq signalling could occur
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via covalent interaction. We tested this hypothesis in intact cells
that lack the complexity of intact vessels, where microanatomic
properties of effect compartments may confound mechanistic
analysis. We incubated HEK293 cells with FR for 1 h, followed by
extensive washing before activation of endogenous Gq-sensitive
muscarinic M3 receptors with CCh. Interestingly, Gq inhibition
was also retained after washout even in this less complex
cell-based experiment (Fig. 6d) indicating formation of a covalent
complex or, alternatively, very tight association of FR with Gq.
To discriminate between these possibilities, we abolished the
reactive moiety by catalytic hydrogenation to afford a reduced
form of FR (Supplementary Fig. 12a, hereafter ‘FR-red’). FR-red
still displayed potent Gq inhibition (Supplementary Fig. 12b), and
this effect remained after washout (Fig. 6e). These results suggest
that the a,b-unsaturated carbonyl group within FR is not crucial
for Gq/11 inhibition and that FR and Gq do not interact in a
covalent way. We therefore posit that a slow off-rate may
contribute signiﬁcantly to the high ‘afﬁnity’ of FR to Gq,
accounting for both pseudo-irreversible inhibition and resistance
to washout in ex vivo vessel preparations as well as in intact cells
in culture.
Docking and molecular dynamics (MD) simulations of FR.
Comprehensive in vitro characterization using pathway-unbiased
and signal-speciﬁc endpoint assays suggest that FR shares several
hallmark features with YM, such as selectivity for inhibition of
Gaq/11/14 isoforms12 or non-covalent interaction with Gq33, yet
information on its molecular mechanism of action is lacking. YM
has recently been co-crystallized in complex with Gaq-bg thereby
providing atomic level insight into its mode of action at a
molecular level12. We took advantage of this information in
combination with molecular docking studies to investigate
whether structural differences between FR and YM might
impact their binding poses within the Gq protein. Binding
energies for both inhibitors determined through independent
docking runs were very similar (9.76 kcalmol 1 versus
9.85 kcalmol 1 for FR and YM, respectively) and the best
scoring docking result of Gq-bound FR aligned well with that
previously determined for YM in complex with Gq (Fig. 7a,b, for
zoomed-out versions of G protein-inhibitor complexes see Fig. 7c
and Supplementary Fig. 13). Consistent with these ﬁndings,
all-atom MD simulations, which build on information from
crystal structures to model protein movements in solution15,34,
revealed that FR occupancy of Gaq reduced local ﬂexibility in
switch region I and II and also did so very efﬁciently in the a4-b6
loop and C-terminal a5 helix, regions known to be crucial for
receptor-mediated G protein activation8,11,35 (Fig. 7d and
Supplementary Fig. 14 for colour coding of all Gaq regions
with impaired domain motions). Movement of Ga switch regions
is critical to commencement of G protein signalling8,11,36 and
impaired ‘switch movement’ would also be entirely consistent
with inhibition of GDP release. We therefore infer that FR likely
functions as guanine nucleotide dissociation inhibitor (GDI), that
is, shares its principal mode of action with YM.
The molecular mechanism of FR action. To test the predictions
from our computational studies we performed binding assays on
M1-CHO cells or membranes isolated from these cells that
express the Gq-activating muscarinic M1 receptor. Whole-cell
binding assays can tell whether or not inhibitors of receptor
function act via perturbation of agonist binding. Membrane-
binding assays further advance mechanistic insight because
they allow distinction between GDIs and GTP entry inhibitors37.
In whole cells, FR did not affect CCh displacement of the
radioantagonist [3H]N-methylscopolamine ([3H]NMS; Fig. 7e).
These data illustrate that inhibition of Gq-GPCR function by FR
is not due to perturbation of agonist binding. In M1-CHO
membranes CCh displacement of [3H]NMS is biphasic because
GPCR agonists bind with high afﬁnity to a fraction of receptors
that are also coupled to G proteins and with lower afﬁnity to
G protein-uncoupled receptors (Fig. 7f)11,37–39. These conditions
can visualize GDI activity: GDIs speciﬁcally inhibit high-afﬁnity
agonist binding, because they preclude ternary complex
formation, that is, short-lived ligand–receptor complexes that
are stabilized by nucleotide-free G proteins. Indeed, while FR had
no effect on the afﬁnity of NMS to M1 receptors (Supplementary
Fig. 15) the Gq inhibitor signiﬁcantly diminished (by 40%)
high-afﬁnity CCh binding, indicating that it interferes with
ternary complex formation of agonist, receptor and G protein
(Fig. 7f). Unexpectedly, FR did not fully abolish high-afﬁnity CCh
binding that can be rationalized if (i) M1 is linked to G proteins
from more than one family, (ii) intracellular adaptors other than
G proteins promote high-afﬁnity agonist binding, or (iii) FR does
not act as GDI and therefore differs mechanistically from YM.
To address this question, we quantiﬁed dissociation of tritiated
GDP from puriﬁed recombinant Gaq proteins that were isolated
from Sf9 cells (Fig. 7g). High concentrations of FR completely
prevented [3H]GDP dissociation with a half effective
concentration of 15 nM (Fig. 7h and Supplementary Table 1 to
demonstrate that [3H]GDP dissociation was independent of the
time point chosen). This directly illustrates that FR acts as a
potent GDI for Gaq.
FR induces G1 cell cycle arrest in melanoma cells with Gq tone.
Inhibition of Gq may represent an effective molecular interven-
tion to target oncogenic signalling at a post-receptor convergence
point, particularly for those tumour cells in which signs of
elevated Gq activity are apparent. The latter may be induced by
aberrant expression of wild-type and/or mutated Gq-GPCRs, as
well as constitutively active Gaq/11 mutants such as Gaq/11R183C
or Gaq/11Q209L, respectively, both considered as oncogenic
drivers in melanomas of the eye and skin40,41. Forced enrichment
of HEK293 cells with GaqR183C and GaqQ209L confers
signiﬁcant elevation of cell-intrinsic IP1 production and this
effect was entirely blunted (GaqR183C) or diminished
(GaqQ209L) by FR (Supplementary Fig. 16). We therefore
applied FR as an indicator to identify melanoma cell lines
with elevated Gq activity using both IP1 production and
phosphorylation of extracellular signal-regulated kinases ERK1/2
(also named MAP kinases) as readouts. We found FR-sensitive
reductions of basal signalling in B16, MZ7 and Hcmel12 but not in
Mamel65, Mamel15, Mamel119 or Skmel28 cells (Fig. 8a,b; for
mutational status of melanoma cells regarding mutant Gaq/11
alleles and key MAP kinase pathway drivers B-Raf and N-Ras, see
Supplementary Table 2). MEK inhibitor, Trametinib (Tra) blunted
ERK phosphorylation in all cell lines, and Vemurafenib (Vem)
inhibited ERK activation only in cell lines harbouring the mutant
B-RafV600E allele, entirely consistent with their associated modes
of action (Fig. 8b). Interestingly, MZ7 cells differ from B16 and
Hcmel12 cells in that IP1 production (Fig. 8a), but not ERK1/2
phosphorylation (Fig. 8b), is FR sensitive. Consistently,
FR-sensitive inhibition of proliferation was only observed for B16
and Hcmel12 cells (Fig. 8c). We conclude that (i) genetic presence
of an activating mutation within Gaq/11 (MZ7 harbours
Ga11R183C, Hcmel12 harbours GaqQ209L) does apparently not
sufﬁce to deﬁne the molecular subtype of melanoma that responds
to Gq inhibition, and (ii) FR effectively suppresses proliferation
even in the absence of mutationally activated forms of Gq. We
therefore investigated the consequences of Gq inhibition for
hallmark behaviours of melanoma cells using the well-established
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B16 line as model system. FR effectively reduced growth of B16
cells in a concentration-dependent manner, as assessed by trypan
blue staining of viable cells (Fig. 8d). Interestingly, in striking
contrast to many other anticancer agents, that show direct
cytotoxicity, FR did not compromise mitochondrial metabolism
(Fig. 8e) suggesting that inhibition of proliferation is achieved
without causing cell death. Consistently, ﬂow cytometry analysis
indicated that FR-treated cells remained viable and retained their
membrane integrity (Fig. 8f). Rather, inhibition of cell growth
resulted from cell cycle arrest in the G1 phase (Fig. 8g,h). Notably,
no evidence for decomposition of FR was obtained during the assay
period (Supplementary Figs 17 and 18), possibly indicating that
nature has evolved this peptide to be rather stable.
FR forces melanoma cells into differentiation. Inhibition of
proliferation via growth arrest and concomitant induction of
differentiation has recently been proposed as a novel strategy to
target oncogenic signalling in brain tumours42. We reasoned that
a similar change in cell fate may have occurred in B16 cells when
treated with FR, because we noted a gradual decrease in cell pellet
volume accompanied by a profound increase in pigmentation
(Fig. 9a). Melanosome-containing pigment organelles were also
evident in light microscopic images of B16 cells cultured or not in
presence of FR (Fig. 9b): FR-treated cells appeared ﬂattened,
rather dark, and packed with melanin vesicles, attributes
consistent with the adoption of a more differentiated state.
Consistently, melanocyte differentiation marker gp100 was
upregulated considerably on FR treatment (Fig. 9c). No signs of
differentiation were observed in MZ7 cells after treatment with
FR in agreement with its lack on proliferation (Supplementary
Fig. 19). These results lead us to suggest that Gq inhibition may
represent a novel avenue to reprogram melanoma cells to a less
aggressive phenotype.
FR inhibits melanoma cell migration. The migratory features of
melanoma cells allow them to spread through lymphatic or blood
vessels and form metastases in distant organs. We therefore
investigated whether inhibition of Gq signalling would also
inhibit melanoma cell migration induced by normal fetal calf
serum (FCS)-containing medium. Vehicle-treated melanoma cells
displayed a strong migratory capacity in boyden chamber trans-
well assays, but this behaviour was lost when cells were pretreated
with FR (Fig. 9d,e). We infer from these data that Gq signalling is
also critically involved in the migration of B16 cells and that
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inhibition of Gq signalling may represent a novel route to
prevent the metastatic spread of melanoma cells with an ‘intrinsic
Gq tone’.
Discussion
Distinct tools and technologies are available today to interrogate
the impact of G proteins in GPCR signal transduction by
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lines) for 2 h. Blue bars show IP1 production stimulated by the pan-G protein activator AlF4
 . Depicted are IP1 levels relative to buffer per 100,000 cells
(MZ7, Skmel28, Mamel65, Mamel119, Mamel 15 and B16) or 10,000 cells (Hcmel12). (b) ERK phosphorylation in the indicated melanoma cells lines that
were non-treated (nt), or pretreated with FR 1 mM, the MEK inhibitor Trametinib (Tra) 1 mM, or the speciﬁc B-Raf V600E inhibitor vemurafenib (Vem) 1 mM
for 1 h, quantiﬁed in a HTRF-based ERK1/2 phosphorylation assay. Melanoma cells that do not harbour the mutated B-Raf V600E allele exhibit paradoxical
ERK activation, consistent with published ﬁndings, for example, ref. 70. (c) Effect of FR (1 mM) and Tra (1 mM) on melanoma cell proliferation. (d) Effect of
different concentrations of FR on the cell growth of B16 cells measured by trypan blue staining. (e) Metabolic activity of B16 cells using the XTTassay after
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absence of FR (10 nM) for 72 h. (d) *Po0.05, **Po0.01, ***Po0.001 according to a two-tailed Student’s t-tests. (a,b,d,h) Meansþ s.e.m. of n¼ 2–5
experiments performed at least in duplicate. (c,e–g) One representative experiment that was at least repeated once.
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preventing activation of their associated downstream signalling
pathways. Among these are minigenes encoding C-terminal Ga
peptide sequences43, dominant negative forms of Ga subunits44,
small interfering or short hairpin RNAs45, and whole organism or
individual cell knockouts46. While results obtained with these
methods have been very insightful, they cannot replace traditional
pharmacological approaches based on target perturbation via
chemical inhibition. The latter provide a valuable and
complementary view on the biological role of proteins of
interest, as they allow a biological readout when proteins are
functionally inhibited but physically intact.
PTX47 and CTX48, two bacterial toxins that mediate their
effects via covalent modiﬁcation of Ga subunits, have been
instrumental in deﬁning and diagnosing contribution of Gi and
Gs proteins to biological processes3,49,50. Both are available to the
research community and have been employed in several thousand
publications to address fundamental questions related to
G protein function. No such tool with general access for
investigators exists for perturbation of Gq proteins. YM254890
(YM), a selective Gq inhibitor12, has been withdrawn by Astellas
Pharma Inc. and was only available to few research laboratories
worldwide. Simpliﬁed YM analogues have recently been
synthesized but they are not as potent as YM and their
selectivity for individual G protein isoforms is unknown51,52.
BIM46187, originally introduced as pan-G protein inhibitor and
experimental anticancer agent, is Gq-preferring but not -selective
and, unfortunately, changes its preference for G protein
inhibition depending on the cellular background in a manner
that is unpredictable at present37. FR, unlike YM, can be obtained
from natural sources that are readily accessible without any
restriction13. We isolated FR from the leaves of the evergreen
plant A. crenata and performed extensive in vitro investigations
to conclude that FR is (i) exceptionally selective for inhibition
of Gq family proteins Gq, G11 and G14, (ii) absolutely
inert on G protein-independent, arrestin-mediated pathways,
(iii) competent to associate with its target Gq via a long-lasting,
pseudo-irreversible interaction, (iv) remarkably stable despite its
peptide nature, (v) functionally efﬁcacious because it acts as GDI,
and (vi) of outstanding value as molecular probe to unravel
contribution of Gq signalling in complex biological processes
in vitro and ex vivo.
For the above reasons we argue that FR can clearly be the
designated molecule to answer the questions as to what happens
when Gq family proteins are inactivated. Biological data on
FR are still scarce53–55 and its mechanism of action or selectivity
for individual G protein isoforms has never been addressed
systematically. Our study provides thorough characterization of
FR and ‘proof-of-principle’ experiments to enable rational
application as Gq/11/14-selective inhibitor by the scientiﬁc
community. ‘Reversibility experiments’ led us to suggest that
FR might bind to Gq in living cells via long-lasting interaction
(Fig. 6). Both in ex vivo vessel preparations as well as in intact
cells in culture FR effects were remarkably resistant to washout.
These results have important implications for development of FR
derivatives with altered Ga selectivity proﬁles because they
suggest that characterization of newly developed Ga probes
should take into account kinetic properties of inhibitor–target
complexes. Indeed, a number of drugs in clinical use gain both
selectivity and long duration of action via slow dissociation
from their respective targets, a behaviour termed ‘kinetic
selectivity’56,57. Although we cannot deliver a direct estimate of
FR dissociation from Gq proteins at present, our data suggest that
FR-Gq complexes dissociate slowly. Nevertheless, reversibility
experiments, as those exempliﬁed herein (Fig. 6a,c,d) may provide
the desired information until suitable radioligands for kinetic
proﬁling will become available.
We were intrigued by the chemical stability of the depsipeptide
FR, which we consider extraordinary. Even if incubated over a
1 10
1
0
250
375
500
***
*** ***
gp100
β-Actin
70 kDa
43 kDa
FR
(nM)
FR
(nM)
100.10.01w/o
125M
ig
ra
te
d 
ce
lls
(pe
r h
igh
 po
we
rfie
ld)
FR (nM)
1010.10.010
w/o
w/o
0.10.01
10 nM
FR
20 μM50 μM
50 μM 20 μM
100 μm
w/o Tra FR
Figure 9 | FR forces melanoma cells into differentiation while simultaneously inhibiting migration. (a) Phenotype of B16 cell pellet after treatment with
various concentrations of FR. (b) Light microscopic images of B16 cells cultured without or with FR (10 nM). (c) Western blot analysis of the melanoma
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period of up to 8 days in cell culture medium no decomposition
was detected (Supplementary Fig. 18). Peptides usually are
metabolically unstable because peptidases attack their amide
bonds. However, the cyclic structure of FR confers signiﬁcant
resistance towards their degradation by peptidases. Additional
features accounting for resistance of FR to degradation
are N-methylations of amide bonds as well as unusual amino
and hydroxy acid building blocks, which differ greatly from
those of normal peptides (Supplementary Fig. 20)58,59.
For the above reasons, FR does not only serve as a
pharmacological agent to exclude Gq activity in assays with
short incubation times, rather FR can be employed to also
investigate contribution of Gq input to cellular processes that
need registration over many hours or days, as is the case in cancer
drug discovery.
Many potent mitogens exert their proliferative signals via
GPCRs that are linked to the Gq family of heterotrimeric G
proteins40,41. The notion that numerous Gq-GPCRs regulate cell
proliferation, but also motility and thereby invasive potential of
cancer cells led us to posit that inhibition of Gq proteins rather
than their linked receptors may be an efﬁcient molecular
intervention to target oncogenic signalling at the post-receptor
level. We tested this hypothesis in the melanoma B16 cell line and
found that selective Gq inhibition was sufﬁcient to attenuate cell
proliferation, while simultaneously skewing cellular responses in
favour of differentiation. Inhibition of cell growth by FR was due
to a G1 cell cycle arrest but not to apoptotic cell death (Fig. 8).
This is in contrast to many anticancer agents that also exert anti-
growth activity via induction of cell death60. The ﬁrst successful
differentiation agent was all-trans-retinoic acid to combat acute
promyelocytic leukaemia61. Recently, forced differentiation of
cancer cells has been proposed as a new approach for brain
tumour therapy42. Our results indicate that FR may hold promise
in the search for alternative melanoma therapies because it uniﬁes
growth arrest with forced differentiation.
Another serious challenge facing cancer treatment is
metastasis, the spread of cancer cells through blood or lymphatic
vessels to distant organs. This feature is intimately linked to the
cell’s capacity to migrate41. Migration, however, is not an intrinsic
property of cells, but rather a highly regulated and coordinated
process orchestrated by numerous extracellular cues, their
receptor targets and their associated signalling networks. The
capacity of cells to move involves changes in cytoskeletal
structure and dynamics with major implication of the G12/13
and Gi-bg signalling axis40. Melanoma B16 cells, however, greatly
rely on Gq for migration, and this cellular behaviour is completely
abolished by FR. It will be exciting to pinpoint these Gq stimuli
in future experiments to compare therapeutic potential of
Gq- versus Gq-GPCR inhibition as rational targeted melanoma
therapy.
In sum, this is, to the best of our knowledge, the ﬁrst
comprehensive study to reveal the experimental value of FR as
tool in probing Gq-sensitive cellular responses with remarkable
speciﬁcity. It provides framework, knowledgebase and solid
foundation for the research community planning to employ FR
as reagent in studies of G protein-mediated signal transduction.
Just as inhibition of cell responses by pretreatment with PTX has
become diagnostic of the involvement of Gi proteins and is
applied worldwide by numerous research laboratories, we
anticipate FR to stand out at least equally for investigations into
the biological relevance of Gq.
Methods
Reagents. Cell culture materials were from Invitrogen, U-46619 and nociceptin
were from Cayman, GSK-1120212 (Trametinib) were from Selleckchem, and all
other reagents were from Sigma Aldrich unless stated otherwise.
Cell culture. All cell lines were cultivated with 5% CO2 at 37 C in a humidiﬁed
atmosphere. All media were supplemented with 10% (v/v) FCS, penicillin
(100Uml 1) and streptomycin (100 mgml 1).
Native and recombinant HEK293 cells were cultivated in Dulbecco’s modiﬁed
Eagle’s medium (DMEM). For CRTH2-HEK293 and GPR55-AD-HEK293,
0.4mgml 1 geneticin (G418; InvivoGen) was added. ratGPR17-HEK293 and
CRTH2-RLuc-GFP2-b-arrestin2-HEK293 were cultivated with 0.5mgml 1
G418, and 56mgml 1 zeocinþ 0.5mgml 1 G418, respectively. Media for
FFA1-Flp-InT-REx293 and FFA2-Flp-InT-REx293 was supplemented with
blasticidin (15 mgml 1)þ hygromycin B (100 mgml 1). Expression from the
Flp-In locus was induced by doxycycline (1mgml 1) for 16–18 h.
CHO cells were cultivated in Ham’s F12 Nutrient Mix (Ham’s F12) with
GlutaMAX. For M1-CHO cells, 0.2mgml 1 G418 was added. FFA4-CHO-Flp-In
cells were generated by stably transfecting CHO-Flp-In cells with pcDNA5FRT
containing HA-tagged FFA4 and pOG44. For FFA4-CHO-Flp-In selection,
hygromycin B (0.4mgml 1) was added.
The autologous human melanoma cell lines MZ7-MEL (MZ7; exhibits
mutations including B-RafV600E and Ga11R183C), Skmel28 (also carries the
B-RafV600E mutation but is wild type for Gaq/11), Mamel15 and Mamel119 (both
wild type for B-Raf and Gaq/11), Mamel65 (carries a N-Ras Q61K mutation, but is
wild type for B-Raf and Gaq/11), and the mouse melanoma cell lines Hcmel12
(carries a mutation in GaqQ209L, but is wild type for B-Raf and N-Ras)
and B16-eGFP, hereafter B16 (wild type for B-Raf and does not exhibit
Gaq/11 mutations), were cultured in Roswell Park Memorial Institute (RPMI)
1640 medium (Life Technologies) supplemented with 2mM L-glutamine, 10mM
non-essential amino acids, 1mM HEPES (all from Life Technologies), 20mM
2-mercaptoethanol (Sigma)62,63. Mutations listed are from the SANGER cancer cell
line project database (http://cancer.sanger.ac.uk/cell_lines) and from inhouse
sequencing.
CHO, HEK293, Skmel28 and B16 cells were from the American Type
Culture Collection. MZ7 cells were kindly provided by Professor Thomas Ho¨lzel,
University of Mainz. Mamel cell lines were kindly provided by Professor Dirk
Schadendorf, University of Essen. The Hcmel12 cell line was generated from a 7,
12-dimethylbenz(a)anthracene-induced melanoma from HGF-CDK4(R24C) mice63.
Melanoma cell lines were routinely authenticated by PCR on characteristic
N-Ras and B-Raf mutations. Hcmel12 cells were routinely authenticated by PCR
on CDK4. All cell lines were tested for mycoplasma contamination by PCR on a
regular basis and were found to be mycoplasma-free.
In vitro morphology was assessed using a TE Eclipse microscope (Nikon).
For inhibitor experiments or pan-G protein activation, cells were pretreated
overnight (50 ngml 1 PTX; 100–200 ngml 1 CTX) or for 60–120min (300 mM
AlF4 ; 1–10 mM FR) unless stated otherwise.
Site-directed mutagenesis. Mutations of the mouse Gaq (GaqR183C and
GaqQ209L) cDNA, HA-tagged in pcDNA3.1(þ ), were generated by quick change
site-directed PCR mutagenesis64 with the following primer (50–30):
GaqQ209L fwd: 50-GATGTAGGGGGCCTAAGGTCAGAGAG-30
GaqQ209L rev: 50-CTCTCTGACCTTAGGCCCCCTACATC-30
GaqR183C fwd: 50-CAACAAGATGTGCTTAGAGTTTGTGTCCCCACCACA
GGGATCATC-30
GaqR183C rev: 50-GATGATCCCTGTGGTGGGGACACAAACTCTAAGCA
CATCTTGTTG-30
Successful mutations were veriﬁed by DNA sequencing.
Generation of Gaq/11 knockout HEK293 cells. Gaq and Ga11, which are encoded
by the GNAQ and the GNA11 genes, respectively, were simultaneously targeted by
a CRISPR-Cas9 system65 with some modiﬁcations. GNAQ-targeting sgRNA
sequence (50-AAACAAGAAAGATCTTCTAGA-30 ; a part of Xba I-recognizing
sequences (TCTAGA) is underlined) was inserted into the Bbs I site of the
pX330-U6-Chimeric_BB-CBh-hSpCas9 vector (pX330; a gift from Feng Zhang,
Broad Institute; Addgene plasmid # 42230) using two synthesized oligonucleotides
(50-CACCGAAACAAGAAAGATCTTCTAG-30 and 50-AAACCTAGAAGATCTT
TCTTGTTTC-30 ; FASMAC, Japan). Similarly, GNA11-targeting sgRNA sequence
(50-AGGGTACTCGATGATGCCGG-30 ; complementary to the gene transcription
direction; Hap II-recognizing sequences is underlined) was inserted using a set of
oligonucleotides (50-CACCGAGGGTACTCGATGATGCCGG-30 and 50-AAACC
CGGCATCATCGAGTACCCTC-30). Correctly inserted sgRNA sequences were
veriﬁed by a Sanger sequencing method (FASMAC, Japan). HEK293A cells were
seeded in a 12-well culture plate at a density of 200,000 cells per well in DMEM 2
(Nissui Pharmaceutical, Japan) supplemented with 10% fetal bovine serum (Gibco,
Thermo Fisher Scientiﬁc) and penicillin/streptomycin and transfected with a
mixture of the GNAQ-targeting vector (0.25 mg), the GNA11-targeting vector
(0.25 mg) and a pGreen Lantern vector encoding a green ﬂuorescent protein
(0.1 mg) using a Lipofectamine 2000 Reagent (Life Technologies, CA, USA).
Twenty-four hours post transfection, the cells were detached and GFP-positive cells
(B30% of injected cells) were isolated using a cell sorter (SH800, Sony, Japan). The
GFP-positive cells were diluted with culture media, seeded in a 96-well plate and
incubated for B2 weeks with addition of fresh media every 5 days. Wells were
routinely checked for their colony appearance and wells containing an apparent
single colony were selected for passages. A half of the detached cells was analysed
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for mutations in the GNAQ and the GNA11 genes using PCR and restriction
enzyme digestion. The following combination of PCR primers and a restriction
enzyme was used to screen mutations: for the GNAQ target, 50-CCGAATGGAG
GAAAGCAAGG-30, 50-ATCAGTTTCAACACGCAGGC-30 and Xba I (TAKARA
BIO, Japan); for the GNA11, and 50-TGTTGCAGCTACCTGACCG-30 , 50-GAG
CCTCTCAGTGCCCCCTC-30 and Hap II (TAKARA BIO, Japan). PCR condition
was 95 C for 2min, followed by 35 cycles of 95 C for 15 s, 64 C for 30 s and 72 C
for 30 s. PCR product (5 ml) was mixed with 0.5 ml of a corresponding restriction
enzyme in a reaction volume of 10 ml at 37 C for 1 h. The digested solution was
applied on 3% agarose gel containing ethidium bromide and separated by
electrophoresis and DNA fragments were visualized under ultraviolet light.
Candidate clones that contained restriction enzyme-resistant PCR fragments were
assessed for functional analysis of Gaq/11 using a TGFa shedding assay66 as well as
Ca2þ response using a FLIPR Calcium 5 Assay Kit (Molecular Devices).
Isolation and puriﬁcation of FR900359. Dried leaves of A. crenata were
extracted three times with methanol (MeOH). The extract was fractionated by
vacuum liquid chromatography over RP18 material using gradient elution from
MeOH:H2O (3/7) to 100% MeOH. The MeOH fraction was subsequently separated
on Sephadex LH-20 with MeOH as eluent. Reversed phase HPLC separation of the
FR containing fraction (column: YMC C18 Hydrosphere, 250 4.6mm, 3 mm;
MeOH:H2O (8:2), 0.7mlmin 1) yielded pure FR (retention time 24min). The
previous commercial name for FR was UBO-QIC.
Stability of FR900359. HPLC was performed on a Waters HPLC system
equipped with an in-line degasser AF, a 600 controller, a 717 plus autosampler, and
a 996 photodiode array detector. The analyses were done using an isocratic method
(80/20 MeOH/H2O; ﬂow: 0.7mlmin 1) with an YMC Hydrosphere RP18 column
(250 4.6mm, 3 mm).
To analyse the stability of 100mM FR in Ham’s F12, the concentration was
analysed at day 0, 3 and 8, relative to 100mM FR in methanol. Ca2þ mobilization
assays were used to determine the stability in cell-based assays.
LC/electrospray ionisation MS measurements. Mass spectra were recorded on
an API 2000 liquid chromatography-tandem mass spectrometry (LC-MS)/MS
spectrometer (electron spray ion source, Applied Biosystems) coupled with an
Agilent 1100 HPLC system using a Phenomenex Luna HPLC C18 column
(50 2.00mm, particle size 3 mm). Compound purity was determined by
HPLC-ultraviolet using the following procedure. A amount of 10 ml of compound
(1mgml 1 in methanol) was injected and eluted with a gradient of water/
methanol containing 2mM ammonium acetate from 60:40 to 0:100 for 10min, and
subsequently with 0:100 for 10min at a ﬂow rate of 300ml min 1, starting the
gradient after 10min. Ultraviolet absorption was detected from 220 to 400 nm
using a diode array detector.
Synthesis of FR900359-red. In all, 10% Pd/C (0.8mg) was added to 1.00mg
(0.998 mmol) FR in MeOH (1ml) and the reaction mixture was stirred under a H2
atmosphere (17 psi) for 9 h. After hydrogenation of the starting material was
completed (monitored by LC-MS) the mixture was ﬁltered (syringe ﬁlter, 0.45 mm,
or a thin pad of celite). The ﬁlter was washed with methanol and the ﬁltrate was
evaporated. The residue was dried in vacuum (10 2mbar) to obtain ‘FR-red’
(PSB-13900) (0.85mg, 0.846 mmol; 85%).
IP1 and cAMP accumulation assay. Quantiﬁcation of intracellular cAMP and IP1
was performed using the HTRF-cAMP dynamic kit and the HTRF-IP1 kit,
respectively, on a Mithras LB 940 reader (Berthold Technologies) according to the
manufacturer’s instructions37. For cAMP assays with M2-CHO cells, the Gi-biased
muscarinic agonist iper-6-phth (ref. 30) was applied.
For washout experiments, cells were pre-incubated for 1 h with FR (1 mM) and
then washed three times for 5min with 750 ml PBS, resuspended in fresh
stimulation buffer, and seeded into a 384-well plate. For IP1 experiments with
Ga14 and Ga16 (UMR cDNA resource center), HEK293 cells were transiently
co-transfected with ORL1 cDNA using FuGENE HD transfection reagent
(Promega).
Calcium mobilization. Intracellular Ca2þ mobilization was measured using the
calcium 5 assay kit (Molecular devices). Brieﬂy, ratGPR17-HEK293 cells (60,000
per well) were seeded (24 h before the assay) into poly-D-lysine (PDL)-coated black
96-well culture plates with clear bottom. Cells were loaded with calcium 5 indicator
dye for 60min, stimulated with MDL29,951 and intracellular calcium mobilization
was detected with the FlexStation 3 Benchtop Multimode Plate Reader.
Stability of FR was tested by either storing FR in cell media or adding FR to the
cell culture ﬂask. Samples were taken for up to 8 days.
Western blot detection of ERK1/2 phosphorylation. In all, 50,000 FFA4-CHO-
Flp-In cells per well were seeded in 6-well plates and incubated overnight at 37 C.
Cells were washed and incubated in serum-free DMEM for 2 h before addition
of vehicle or TUG891 (10mM ﬁnal) for 5min. Media were replaced by Tris-buffered
saline (TBS) containing 1% NP-40, 0.5% sodium deoxycholate, phosphatase and
protease inhibitors (Complete, Roche Diagnostics). Lysates were cleared by
centrifugation at 20,000g for 20min. A amount of 2mg protein (of the supernatant)
of each sample was separated by SDS–PAGE on 10% gels that were transferred to
polyvinylidene diﬂuoride, blocked and probed with antibodies for pERK1/2 (#9101)
and total ERK1/2 (#9102) at 1:1,000 dilution (Cell Signaling Technology). Blots were
scanned and bands were quantiﬁed using Alphaimager software (Alpha Innotech).
HTRF-based ERK1/2 phosphorylation assay. Quantiﬁcation of phosphorylated
ERK1/2 levels was performed using the phospho-ERK (Thr202/Tyr204) cellular
assay kit (Cisbio). Melanoma cells were seeded into 96-well plates at a density
of 25,000 or 50,000 cells per well and cultured overnight. The next day, medium was
aspirated and cells were treated with 1mM FR, 1mM Trametinib, 1mM Vemurafenib,
or medium for 1 h at 37 C. Subsequently, medium and inhibitors were removed and
50ml lysis buffer were added to each well. The plates were incubated for 30min at
room temperature with shaking to lyse the cells and then frozen overnight at
 20 C. Lysates (16ml) were transferred to a white 384-well plate. Anti-phospho-
ERK1/2-d2 (2ml) and anti-phospho-ERK1/2-Eu3þ -cryptate (2ml) were added to
each well and plates were incubated in the dark for 2 h at room temperature. Time-
resolved ﬂuorescence resonance energy transfer (FRET) signals were measured using
the Mithras LB 940 multimode reader (Berthold Technologies).
Melanoma immunoblots. Melanoma cells were seeded into 6-well plates in
complete RPMI medium. Six hours after seeding cells were treated with 1 mM FR,
1 mM Trametinib, or medium for 72 h at 37 C to analyse gp100 and micro-
phthalmia-associated transcription factor (MITF) expression. Melanoma cells were
directly lysed in Laemmli buffer and subsequent incubation for 5min at 95 C.
Total cell lysates were separated using 10% SDS–PAGE and proteins were
transferred to a nitrocellulose membrane (GE Healtcare) by wet blotting (BioRad
Mini-PROTEAN Tetra handcast system). After 1 h of blocking with 5% bovine
serum albumin (GE Healtcare) in TBS with 0.5% Tween-20, membranes were
incubated with primary antibodies overnight at 4 C. Corresponding secondary
antibodies and the Odyssey Sa Imaging system (LI-COR Biosciences) were used for
protein detection. Primary antibodies: b-Actin (C4, Santa Cruz sc-47778) at 1:1,000
dilution, gp100 (abcam ab-52058) at 1:500 dilution and microphthalmia-associated
transcription factor (MITF) (abcam ab-24875) at 1:1,000 dilution, secondary
antibodies (all provided by LI-COR Biosciences): donkey anti-mouse IRDye 680
LT, donkey anti-goat IRDye 800 CW.
Label-free cellular-based assays. DMR was recorded with the Corning Epic
biosensor30,31 or with the PerkinElmer Ensight with the following modiﬁcations:
for HEK293, CRTH2-HEK293 and FFA1-HEK293, 15,000, 18,000 and 18,000 cells
per well, respectively, were seeded 18–24 h before experiment. For GPR55-HEK293
cells, 12,000 cells per well were seeded 48 h before experiment and after 24 h media
was replaced by assay buffer for starvation conditions.
Bioimpedance (CellKey) assays were performed67 with the following
modiﬁcations: 11,000 (3,000 for CRTH2-HEK293 and FFA1-Flp-InT-REx293) cells
per well were seeded on PDL-coated 384-well biosensor plates for 18–24 h to grow
to conﬂuence. GPR55-HEK293 cells were seeded 48 h before the assay and after
24 h medium was replaced by assay buffer (Hank’s Balanced Salt Solution (HBSS)
with 20mM HEPES).
Bioluminescence resonance energy transfer. Receptor and G protein
constructs were transiently co-transfected into HEK293 or HEK293T cells using
polyethylenimine (Polysciences Inc.). Generation of G protein BRET probes was
described previously in detail17,18 (see references within). Forty-eight hours after
transfection, cells were washed and resuspended in PBS with 0.1% (w/v) glucose at
room temperature. Cells were pretreated with 100 nM FR or vehicle for 30min and
then distributed (70–80 mg of protein per well) in a 96-well microplate (Wallac,
PerkinElmer Life and Analytical Sciences) and incubated in the presence of
increasing doses of ligands for 2min. BRET2 between RLuc8 and GFP10 or between
RLucII and GFP10 was measured after the addition of the RLuc substrate
coelenterazine 400a (5 mM, Interchim). BRET2 readings were collected using a
modiﬁed Inﬁnite F500 (Tecan Group Ltd), a Mithras LB 940 multimode reader
(Berthold Technologies), or a Synergy2 (BioTek) microplate reader. The BRET2
signal was calculated as ratio between GFP10 emission and the light emitted by
Rluc8 or RlucII, respectively. The changes in BRET induced by the ligands were
expressed on graphs as ‘ligand-promoted BRET’ using the formula: ‘BRET ratio
with ligand—BRET ratio without ligand’.
To estimate b-arrestin2 recruitment to FFA4, plasmids encoding FFA4 fused to
enhanced yellow ﬂuorescent protein at its C-terminus and b-arrestin2 fused to
Renilla luciferase were co-transfected into HEK293 cells. Twenty-four hours post
transfection, cells were distributed into white 96-well plates and then maintained in
culture for another 24 h before their use. To conduct the assay, cells were ﬁrst
washed in HBSS before addition of Renilla luciferase substrate coelenterazine h
(5 mM) and the ligand of interest. Cells were incubated at 37 C for 30min before
luminescence at 535 and 475 nm was recorded using a Pherastar FS. The ratio of
luminescence at 535/475 nm was then used to calculate the BRET response.
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For BRET2 assays on HEK293 cells stably expressing CRTH2-Luc and
GFP2-b-arrestin2, cells were detached and resuspendend in HBSS with 20mM
HEPES at a density of 1.06 106 cells per ml. Cell suspension (170 ml) was
distributed into white 96-well microplates and incubated in the presence of 10 ml
buffer or agonist for 5min before substrate addition. DeepBlueC coelenterazine
(Gold Biotechnology, MO, USA; 20 ml per well) was injected by injector 3 to yield a
ﬁnal concentration of 5 mM. To detect BRET, light emissions at 400 and 515 nm
were measured sequentially using a Mithras LB 940 instrument. The BRET signal
(BRET ratio) was determined by calculating the ratio of the light emitted by the
ﬂuorescence acceptor (515 nm) and the light emitted by Rluc (400 nm). The cells
were pretreated with PTX for 16–20 h and FR for 30min.
Radioligand binding. For whole-cell binding assays39, M1-CHO cells
were collected and 70,000 cells per well were incubated with 0.2 nM
[3H]N-methylscopolamine ([3H]NMS; PerkinElmer Inc.) and different
concentrations of non-labelled competitor with or without 1 mM FR in assay buffer
(HBSS supplemented with 20mM HEPES; pH 7.0) in a 96-well microtiter plate
(Fischer Scientiﬁc GmbH) at 28 C in a ﬁnal volume of 300 ml for 2 h. For
radioligand binding experiments performed with CHO-M1 mebranes39,68,
membranes (20–40 mgml 1) were incubated with 0.2 nM [3H]NMS and different
concentrations of non-labelled competitor with or without 1 mM FR in a HEPES
buffer (10mM HEPES, 10mM MgCl2, 100mM NaCl, pH 7.4) at 30 C in a ﬁnal
volume of 300 ml for 2 h in a 96-well microtiter plate.
Binding experiments were terminated by rapid vacuum ﬁltration through a
glass ﬁbre ﬁlter (PerkinElmer Inc.) and ﬁlter-bound radioactivity was determined
by solid scintillation counting. Non-speciﬁc binding was determined in presence of
10mM atropine.
Gaq puriﬁcation. GaqD34 (containing the ﬁrst 28 residues of rat Gai1 fused to
mouse Gaq lacking the ﬁrst 34 residues, and with a TEV-cleavage site between the
Gai1 and Gaq sequences) was puriﬁed after expression from a pFastBac1 vector in
insect cells37. Puriﬁed GaqD34 (B7mgml 1) was stored at  80 C in 20mM
HEPES pH 8, 0.2mM dithiothreitol, 2% (v/v) glycerol, 100mM NaCl, 0.1mgml 1
PMSF augmented with 10mM NaF, 30 mM AlCl3, and 5mM MgCl2.
GDP exchange assay. [3H]GDP exchange by Gaq was measured based on
previous protocols12,37. Brieﬂy, puriﬁed GaqD34 (100 nM) was incubated with
1 mM [3H]GDP (42,500 c.p.m. pmol 1) and 50mM (NH4)2SO4 for 18 h at 20 C in
assay buffer A (50mM HEPES pH 7.5, 1mM EDTA, 0.9mM MgSO4, 1mM
dithiothreitol, and 0.05% Genapol C-100). Excess [3H]GDP was removed from Gaq
using a ZebaTM spin desalting column following the manufacturer’s protocol
(Thermo Scientiﬁc). Approximately 20% of Gaq incorporated the radiolabelled
nucleotide. The reaction mixtures were then mixed with the same volume of assay
buffer A in the presence of 0.1–2% dimethylsulphoxide (DMSO), 0–200 nM FR and
1.5M (NH4)2SO4 to reach ﬁnal concentrations of 0.5–1% DMSO, 0–100 nM FR
and 750mM (NH4)2SO4 in the reaction. Dissociation of [3H]GDP was monitored
at 20 C by stopping the reaction by addition of 4ml of an ice-cold wash buffer
(20mM Tris pH 8.0, 100mM NaCl and 2mM MgSO4). The quenched mixtures
were ﬁltered through nitrocellulose membranes, the membranes were washed four
times with ice-cold wash buffer, and the ﬁlters air-dried for at least 10min.
Radioactivity was quantiﬁed by scintillation spectrometry.
Nucleotide dissociation. Nucleotide dissociation assays were performed with
AtGpa1 (pPROEXHTb-AtGpa1DN36) that was expressed in and puriﬁed from
BL21(DE3)PLysS Escherichia coli. Assays were carried out in a ﬁnal volume of
1.5ml PBS (25mM potassium phosphate, 100mM KCl, pH 7.0) containing 200 nM
20-O-(N-methylanthraniloyl)-guanosine 50-diphosphate (MANT-GDP) in a quartz
cuvette15. Brieﬂy, puriﬁed AtGpa1 was equilibrated with either DMSO or FR in
DMSO for 20min at room temperature. Equilibrated protein mix was added to the
cuvette containing MANT-GDP and observed for full loading of ﬂuorescent
nucleotide. To initiate MANT-GDP dissociation, 10 mM unlabelled GDP was added
and the loss of FRET emission quantiﬁed.
Fast quantitative cysteine reactivity. Puriﬁed AtGpa1 (1.8 mM ﬁnal) was
pre-equilibrated with either DMSO or FR (10 mM ﬁnal) for 20min at room
temperature before dilution in cold PBS (pH 7.0) with 50 mM GDP and chilled on
ice. 4-(aminosulfonyl-7-ﬂuoro-2,1,3-benzoxadiazole (ABD; TCI America; A5597)
was added (1mM) to the chilled protein mix and distributed to pre-chilled PCR
strip tubes. Unfolding was carried out in a gradient thermocycler (Biometra
TProfessional Thermocycler) for 3min at indicated temperatures from 27 to 67 C,
transferred back to ice, and ABD labelling quenched by addition of 0.1N HCl
(ref. 69). Samples were transferred to a 384-well plate and ABD ﬂuorescence
measured in a BMG Labtech PHERAstar plate reader (excitation: 400 nm;
emission: 500 nm).
Isometric force measurements. Mouse tail artery was dissected and cut into
2-mm-long rings in cold (4 C) low-calcium physiological saline solution con-
taining 118mM NaCl, 5mM KCl, 1.2mM MgCl2, 1.5mM NaH2PO4, 0.16mM
CaCl2, 10mM glucose and 24mM HEPES, pH 7.4. Arterial rings were mounted on
a small vessel wire myograph (Multi Myograph 610M, Danish Myo Technology).
A computer-assisted normalization protocol was exerted to pre-stretch vascular
rings to 0.9 L100 with L100¼ diameter mimicking a transmural pressure of
100mmHg. Rings were equilibrated for 20min in physiological saline solution:
118mM NaCl, 5mM KCl, 1.2mM MgCl2, 1.5mM NaH2PO4, 1.6mM CaCl2,
10mM glucose and 24mM HEPES, pH 7.4. The solution was bubbled with 100%
oxygen and heated to 37 C. Before the experiments, tail arteries were maximally
contracted with PE (10 mM).
Cell proliferation assays. For analysis of the proliferation of human and mouse
melanoma cells, cells were seeded into 6-well plates (1 105 per well) in complete
RPMI medium. Six hours later FR or GSK-1120212 (Trametinib) was added in
indicated concentrations. Control groups were left untreated. After 72 h cells
were collected and viable cells were counted using trypan blue.
For analysis of growth properties of HEK293 cells, 105 HEK 293 cells per well
were seeded on a 6-well tissue culture plate. After 3 h cells were treated with either
10 mmol FR or 0.1% DMSO. After 72 h cell number was determined by counting in
a Neubauer chamber.
Cell viability assays. B16 cell viability in the presence of various concentrations
of FR was measured using the XTT-based cell proliferation kit II (Fa. Roche)
according to the manufacturer’s protocols37. Viability of HEK293 cell lines was
assessed using a ﬂuorimetric detection of resoruﬁn (CellTiter-Blue Cell Viability
Assay, Promega). Speciﬁcally, Gaq/11 ko-HEK293 and HEK293 cells were seeded at
a density of 20,000 and 25,000 cells per well into black 96-well poly-D-lysine-coated
plates with clear bottom, respectively. Three hours after seeding cells were treated
with 0.3% DMSO or FR dissolved in medium for 24 h. To detect cell viability,
CellTiter-Blue reagent was added and cells were incubated for 1 h at 37 C
according to the manufacturer’s instructions. Fluorescence (excitation 560 nm,
emission 590 nm) was measured using a FlexStation 3 Benchtop Multimode Plate
Reader and data were expressed as percentage of cell viability relative to DMSO
control.
Flow cytometry. B16 cells were seeded into 6-well plates (1 105 per well) in
complete RPMI medium. 6 h later FR was added in various concentrations. Control
groups were left untreated. After 72 h cells were collected and apoptosis induction
and cell cycle arrest was analysed using standard protocols with annexin V
(BD PharMingen) and propidium iodide. Data were acquired with a FACSCanto
ﬂow cytometer (BD Biosciences) and analysed with FlowJo software (TreeStar,
V7.6.5 for Windows).
For apoptosis analysis of HEK293 cells, cells were stained for Annexin V by use
of the Annexin V-FITC Apoptosis Detection Kit (Calbiochem) according to the
manufacturer’s instructions.
Immunoﬂuorescence stainings of HEK cells. Cells grown on coverslips were
ﬁxed with 4% paraformaldehyde in PBS and stained with antibodies as follows
(in 0.2% Triton X in PBS, supplemented with 5% donkey serum; 2 h at room
temperature): Ki67 MIB-1 (1:200, Covance) and vimentin (1:1,000, Chemicon).
Primary antibodies were visualized by secondary antibodies conjugated to Cy5
(1:400, Jackson ImmunoResearch) diluted in 1 mgml 1 Hoechst 33342 (nuclei
staining) at room temperature for 1 h. For documentation an inverted ﬂuorescence
microscope (Axiovert 200; Carl Zeiss MicroImaging, Inc.) equipped with a slider
module (ApoTome; Carl Zeiss MicroImaging, Inc.), using ﬁlters for DAPI, GFP,
Cy3 and Cy5, x25, x40 DIC Plan Apochromat oil objectives, an ebx 75 light source
and an AxioCam MRm digital camera was used. Pictures were generated with the
Axiovision Rel. 4.8 software (Zeiss).
Transwell migration assay. Migration of B16-eGFP cells was quantiﬁed using
transwell assays. Brieﬂy, 5 104 melanoma cells in 250 ml RPMI 1640 with 1% FCS
were placed in the upper chamber of uncoated polyethylene terephthalate (PET)
ﬁlters (BD Biosciences, 8 mm pore size) in a 24-well plate and subsequently incu-
bated at 37 C/5% CO2 to adhere. Six hours later, FR was added in various con-
centrations. RPMI containing 1% FCS was added to the lower chamber. Twenty-
four hours later, cells in the upper chamber were removed by cotton swab.
Transmigrated cells on the lower surface of the membrane were counted in three
high-power ﬁelds (magniﬁcation  100) using a TE Eclipse microscope (Nikon).
Modelling. For docking studies we used a YM254890-based structure derived from
pdb 3ah8 (ref. 12). Therefore, the respective residues of YM were modiﬁed and
geometry optimized using a semi-empirical quantum mechanics approach that is
implemented in Yasara’s YAPAC module (Yasara ‘structure’ 14.5.1). The target
protein structure was also derived from the crystal structure of the Gaqbg-YM
complex12 (pdb 3ah8). Docking was performed on the heterotrimeric Gaq/bg
complex using autodock VINA default parameters. The set-up was done with the
YASARA molecular modelling program, and the best scoring result of 24 docking
runs was subjected to further analysis. To guide the docking runs, the docking cell
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was placed around the YM binding epitope revealed by Nishimura et al.12 Ligands
and receptor residues were kept ﬂexible during the docking runs. Structural
alignments were performed with the MUSTANG or Theseus algorithm. Molecular
dynamic simulations were performed with the YASARA molecular modelling
program (Yasara ‘structure’ 14.5.1). Hydrogen bond analysis was performed after
energy minimization of the inhibitor-protein complex in explicit water, using the
particle-mesh Ewald (PME) method to describe long-range electrostatics at a cutoff
distance of 7.8 Å and the Yasara2 force ﬁeld at physiological conditions (0.9%
NaCl, 298 K, pH 7.4).
MD simulations. The structures (Gaq-FR and Gaq only) were equilibrated for
about 80 ns in explicit water using particle-mesh Ewald (PME) method to describe
long-range electrostatics at a cutoff distance of 7.86Å and the AMBER03 force
ﬁeld at physiological conditions (0.9% NaCl, 298 K, pH 7.4) followed by a 40 ns
production run. Simulation time step interval was chosen as 2.5 fs. Supplementary
Fig. 21 illustrates that the timescale of our simulations is sufﬁcient as illustrated
by the RMSD time traces. Molecular graphics were created with YASARA
(www.yasara.org) and POVRay (www.povray.org).
Data analysis. All data were analysed using GraphPad Prism Version 5.00, 5.01 or
6.05 (Graphpad Software, Inc). Data points from concentration-effect relationships
of individual functional experiments or radioligand binding studies were ﬁtted to a
four parameter logistic function (equation (1)) with a subsequent extra-sum-of
squares F-test to decide whether the steepness of the curve differed from  1
(Po0.05).
Y ¼ bottomþ ðtop bottomÞ
1þ 10ððlog EC50Þ xÞnH ð1Þ
For radioligand displacement studies with [3H]NMS or [3H]iperoxo performed in
membranes of CHO-M1 cells, an extra-sum-of-squares F-test was conducted to
decide whether the data points were best described using a one site competition
(equation (2)) or a two site competition (equation (3); F-test, Po0.05).
Y ¼ bottomþ ðtop bottomÞ
1þ 10ððlog EC50Þ xÞ ð2Þ
Y ¼ bottomþ span fraction1
1þ 10ðx logðEC50 1ÞÞ
 
þ span ð1 fraction1Þ
1þ 10ðx logðEC50 2ÞÞ
 
ð3Þ
All data presented are mean values±s.e.m. of n independent experiments, unless
stated otherwise. Comparison between two experimental groups was based on a
two-tailed Student’s t-test. P values were considered as signiﬁcant (*) if Po0.05, as
very signiﬁcant (**) if Po0.01 and as extremely signiﬁcant (***) if Po0.001.
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